News
Two studies provide ‘building blocks’ for future advances in pancreatic cancer
Two recently published studies have provided insights into new ways of tackling pancreatic ductal adenocarcinomas (PDACs), a cancer where survival outcomes have made little progress in the past few decades.…
Roundtable ‘grasps nettle’ on European cancer inequalities
Improving treatment of older patients and closing the East−West divide were the focus of a Community 365 Roundtable on Inequalities organised by the European Cancer Organisation on the 14th October.…
Gut microbiome positively influences abiraterone response in prostate cancer
Abiraterone acetate (AA), an agent used in castrate-resistant prostate cancer, promotes a shift towards health-associated, anti-inflammatory gut commensal bacteria, finds a study in Nature Communications. “These findings clearly demonstrate that…
Four steps to eliminating HPV-related cancers: a call for action
A new report underlines that vaccination, screening, treatment and public awareness, provide the cornerstone for eliminating cancers linked to the human papillomavirus (HPV) in Europe. The report was published by…
Cancer deaths fall, health disparities persist, cancer research affected, reports AACR
The American Association for Cancer Research (AACR) annual Cancer Progress Report for 2020, published 23 September, portrays a mixed picture. On a positive note, the report features advances in cancer…
Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide
In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and…
Combined therapies offer the key to drug-resistant cancer
For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated…
New European Code of Cancer Practice defines patient rights along the cancer pathway
The European Code of Cancer Practice was launched on 23rd September in Brussels by the European Cancer Organisation to empower citizens with 10 key ‘overarching’ rights and reduce cancer care…
Preclinical model identifies predictors of checkpoint inhibitor response
A study published in PNAS (Chen IX, et al. PNAS 2020) of a new mouse model has enabled the identification of distinct gene signatures that distinguish responders from non-responders to…
New transatlantic partnership to regain the momentum of cancer research
Building on the existing Cancer Research UK (CRUK) Grand Challenges initiative, a broader international collaboration has now been forged in partnership with the National Cancer Institute (NCI) in the US.…